新辅助化疗对乳腺癌组织中雌激素、孕激素受体及P53和CerbB-2表达的影响

Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer

目的探讨新辅助化疗对乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)及 P53和CerbB-2表达的影响。方法 2003年1月—2005年12月共有123例手术的乳腺癌患者进入本组研究,分析患者术前弹射式空芯针穿刺活检标本和术后大体标本癌组织中 ER、PR、P53和 CerbB-2表达的变化。结果患者新辅助化疗前 ER 阳性表达率46.61%(55/118),化疗后 ER 阳性表达率66.10%(78/118),两者比较差异有统计学意义(P<0.05);新辅助化疗前后 PR、P53和 CerbB-2的表达无显著性变化(P>0.05)。结论新辅助化疗能使部分乳腺癌组织中的 ER 表达发生改变,但对PR、P53及 CerbB-2的表达无影响。

Objective To study the effect to neoadjuvant chemotherapy on estrogen receptor （ER）, progesterone receptor （PR）, P53 and CerbB-2 expression in patients with breast cancer. Methods From 123 breast cancer patients treated with neoadjuvant chemotherapy, core needle biopsy samples before the chemotherapy and surgical specimens were obtained for assay of ER, PR, P53 and CerbB-2 expression. Results ER expression occurred in 46.61% （55/118 ）of the patients before neoadjuvant chemotherapy and in 66. 10% （78/118）of these after surgery showing statistically significant. But the changes in PR, P53 and CerbB-2 expression exhibited no significant difference. Conclusions Significant changes occur in ER expression after neoadjuvant chemotherapy in patients with breast cancer. Neoadjuvant chemotherapy has no significant effects on PR, P53 and CerbB-2 expression in patients with breast cancer.